Canadian firm Tekmira Pharmaceuticals has commenced manufacturing a drug which is aimed at treating the Ebola-Guinea virus, which has so far claimed the lives of close to 5,000 people, primarily in west Africa.
According to news agency Reuters, Tekmira said last Tuesday that the new drug, part of its TKM-Ebola programme, would be available by early December. Tekmira has completed the design of a modified RNAi (ribonucleic acid interference) drug that targets the Ebola-Guinea variant and works by preventing the virus from replicating. The European Medicines Agency said…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
